medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2011, Number 1

<< Back Next >>

Rev Invest Clin 2011; 63 (1)

Core binding factor acute myeloid leukemia (CBF-AML) in México: A single institution experience

Ruiz-Delgado GJ, Macías-Gallardo J, Lutz-Presno J, Garcés-Eisele J, Hernández-Arizpe A, Montes-Montiel M, Ruiz-Argüelles GJ

Language: English
References: 26
Page: 25-30
PDF size: 65.60 Kb.


ABSTRACT

Twenty one patients with CBF-AML presented prospectively in the Centro de Hematología y Medicina Interna de Puebla (Puebla, México) between February 1995 and March 2010, 14 with the t(8;21)(q22;q22) and 7 with the inv(16)(p13;q22)/ t(16;16)(p13;q22); they represent 13% of all cases of AML. The median age of the patients was 24 years (range 1 to 61). Seven of 14 patients with t(8;21)(q22;q22) had an M2 morphology whereas 3/7 with the inv(16) had an M4 morphology; in addition to the myeloid markers identified by flow-cytometry (surface CD13, surface CD33, and cytoplasmic myeloperoxidase) lymphoid markers were identified in the blast cells of 8/14 cases of the t(8;21) patients, but in no patient with the inv(16). Nineteen patients were treated with combined chemotherapy and 16 (84%) achieved a complete molecular remission. Seven patients were auto or allografted. Relapses presented in 10/16 patients. The median probability of overall survival (OS) has not been reached being above 165 months, whereas the 165- month probability of OS and leukemia-free survival was 52%; despite a tendency for a better outcome of patients with the t(8;21), there were no significant differences in survival of patients with either the t(8;21) or the inv(16). In this single institution experience in México, we found that the CBF variants of AML have a similar prevalence as compared with Caucasian populations, that the co-expression of lymphoid markers in the blast cells was frequent in the t(8;21) and that these two AML subtypes were associated with a relatively good long-term prognosis. Further studies are needed to describe with more detail the precise biological features of these molecular subtypes of acute leukemia.


REFERENCES

  1. Dombret H, Preudhomme C, Boissel N. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr Opin Hematol 2009; 16: 92-7.

  2. Mrozek K, Marcucci G, Paschka P, Bloomfield CD. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 2008; 20: 711-8.

  3. Ruiz-Argüelles GJ, Morales-Toquero A, Manzano C, Ruiz-Delgado GJ, Jaramilo O, González-Carrillo M, Reyes-Núñez V. t (8;21) (q22;q22) acute myelogenous leukemia in México: A single institution experience. Hematology 2006, 11: 235-8.

  4. Ruiz-Argüelles GJ, Ruiz-Delgado GJ. Leucemias agudas. In: Ruiz-Argüelles GJ (Ed.). Fundamentos de Hematología. 4th Ed. México: AMEH. Editorial Médica Panamericana; 2009, p. 143-58.

  5. Ruiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 1992; 50: 735-43.

  6. San-Miguel JF, Duque R. Utilidad del inmunofenotipo en el diagnóstico y clasificación de las leucemias agudas. In: Ruiz- Argüelles GJ, San-Miguel JF (Eds.). Actualización en leucemias. México: Editorial Médica Panamericana; 1996, p. 25-34.

  7. Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H, Kamada N, Ohki M. Junctions of the AML1/MTG8 (ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 1993; 82: 1270-6.

  8. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Pérez-Romano B, Ruiz-Argüelles A, Ramírez-Cisneros F, López-Martínez B, et al. Assessment of residual disease in acute leukemia by means of polymerase chain reaction: A prospective study in a single institution. Rev Invest Clín Méx 2000; 52: 118-24.

  9. Claxton DF, Liu P, Hsu HB, Marlton P, Hester J, Collins F, Deisseroth AB, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 1994; 83: 1750-6.

  10. Ruiz-Argüelles GJ, Apreza-Molina MG, Alemán-Hoey DD, Gómez-Almaguer D, Marín-López A, Mercado-Díaz L. Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: A multicentre study. Eur J Haematol 1995; 54: 18-20.

  11. Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Ruiz- Argüelles A, Pérez-Romano B, Rivadeneyra L. Results of an autologous non-cryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: A single institution, 10-year experience. Act Haematolog 2003; 110: 179-83.

  12. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez Rangel JD, Vela-Ojeda J, Cantú-Rodríguez OG, Jaime-Pérez JC, González- Llano O, Herrera-Garza JL. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: A prospective study. Leukemia Lymphoma 2004; 45: 1191-5.

  13. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457-63.

  14. Ruiz-Arguelles A, Duque RE, Orfao A. Report on the first Latin American Consensus Conference for flow cytometric immunophenotyping of leukemia. Cytometry 1998; 34: 39-42.

  15. Ruiz-Argüelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A. Report of the second Latin American Consensus Conference for flow cytometric immunophenotyping of hematological malignancies. Cytometry 2005; 70B: 39-44.

  16. Stone RM, O´Donell MR, Sekers MA. Acute myeloid leukemia. In: Broudy VC, Berliner N, Larson RA, Leung LL (Eds.). Hematology 2004. American Society of Hematology Education Program Book. Washington D.C.: American Society of Hematology; 2004, p. 98-117.

  17. Ruiz-Argüelles GJ. Promyelocytic leukemia in Mexican mestizos. Blood 1997; 89: 348-9.

  18. Almaguer-Gaona C, Cantú-Rodríguez OG, Hernández-Garza NE, Gómez-Almaguer D. Leucemia aguda. Observaciones epidemiológicas en el Hospital Universitario de la Universidad Autónoma de Nuevo León. Medicina Univ 1998; 1: 15.17.

  19. Ruiz-Argüelles GJ, Gómez-Almaguer D, Delgado-Lamas JL, Gil-Rondero C, Almaguer-Gaona C, Apreza-Molina M.G. High frequency of acute promyelocytic leukemia in Mexican mestizos. A multicenter study. Blood 1997; 90(Suppl 1): 233b.

  20. Piedras J, López-Karpovitch X, Cárdenas MR.: Cellular immunophenotypes in 97 adults with acute leukemia. Rev Invest Clín Méx 1997; 49:457-64.

  21. Ruiz-Argüelles GJ, Morales-Toquero A, Gómez-Rangel JD, López-Martínez B, Ruiz-Delgado GJ, Reyes-Núñez V. Treatment of acute promyelocytic leukemia: A single institution experience. Rev Invest Clín Méx 2005; 57: 415-9.

  22. Nucifora G, Rowley JD. AML1 and the 8:21 translocation in acute and chronic myeloid leukemia. Blood 1995; 86: 1-14.

  23. Kita K, Nakase K, Miwa H. Phenotypical characteristics of acute myelocytic leukemia associated with the t (8;21) (q22;q22) chromosomal abnormality: Frequent expression of immature B cell antigen CD19 together with stem cell antigen CD34. Blood 1992; 80: 470-7.

  24. Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B Study. J Clin Oncol 2005; 23: 5705-17.

  25. Swansbury GJ, Lawler SD, Alimena G. Long-term survival in acute myelogenous leukemia. A second follow up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994; 73: 1-7.

  26. Lobato-Mendizábal E, Ruiz-Argüelles GJ, Ganci-Cerrud G, Gómez-Almaguer D, Lozano-de-la-Vega A, Labardini-Mendez J. Tratamiento a largo plazo y factores pronósticos en leucemia aguda mieloblástica del adulto. Experiencia del grupo INNSZ (Puebla-Monterrey-México). Rev Invest Clin Méx 1991; 43: 215-22.




2020     |     www.medigraphic.com